BGPT: Author Review: Dragan Maric

Explore by Goal

Quick Explanation Copied

Dragan Maric is a recurring co-author on multiple high-impact neuroscience and neurobiology papers (Nature 2021, NEJM 2020, Sci Transl Med 2015, Mol Cell 2019, Nat Neurosci 2017), indicating regular contribution to well-cited collaborative research teams rather than solely first-author programmatic leadership — examples below link to each paper.

Long Explanation

Author Review — Dragan Maric (evidence-based synthesis)

Evidence highlights (visual then key facts)

Nature 2021: "A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis" — high-profile mechanistic/clinical neuropathology study; Maric is middle author, indicating collaborative contribution to neuroimmunology and brain tissue analysis.
NEJM 2020 letter/study: brain microvascular injury in COVID-19 decedents — rapid-response neuropathologic reporting in a major clinical journal; demonstrates ability to produce clinically-relevant neuropathology findings under time pressure.
Sci Transl Med 2015: HERV-K and ALS — translational molecular neuropathology with mechanistic assays and human samples; again Maric is a co-author of a multidisciplinary team.
Mol Cell 2019: control of ULK1 activation — mechanistic cell-biology work illustrating competence in molecular pathways relevant to autophagy.
Nat Neurosci 2017: iPSC-derived microglia methods — indicates technical capability in stem-cell derived models and neuroimmune cellular modeling.

Author-level metrics and what they mean (data sources: provided author summary + OpenAlex top-works)

Paper count (provided snapshot): 47 research papers (author-supplied list) — shows an active publication record in neurology, neuro-oncology, neuroimmunology, and cell biology across ~15+ years.
Citation footprint (provided snapshot): total citations ~1,501 for the 47-paper snapshot — concentrated citation impact arises from collaborative co-authorship on multiple highly-cited papers (see plotted counts) rather than many singly-cited niche papers.
h-index (author snapshot): 14 — indicates a moderate record of papers with at least that many citations; contrasted with OpenAlex top author variants that list other people with the same name (open-author disambiguation issues are common and must be handled carefully when assessing metrics).

Note: Author disambiguation is a major blindspot in bibliometrics; OpenAlex returns multiple 'Dragan Maric' identities with varying h-index/work counts, so verifying identity via ORCID or institutional affiliation is essential before using metric values for personnel decisions.

Strengths — evidence-based

Consistent participation in high-visibility team science across neurology and cell biology (Nature, NEJM, Mol Cell, Sci Transl Med, Nat Neurosci) — suggests strong collaborative and technical contributions ().
Breadth across translational neuropathology (COVID-19 brain pathology), neurodegeneration (HERV-K/ALS, Tau/ApoER2 work in Alzheimer’s-related studies), and tumor biology (glioblastoma/epigenetics papers in the provided list) — multidisciplinary reach is visible in the paper titles provided ().

Weaknesses, blindspots, and caveats

Authorship position: Many listed works show middle-author roles; fewer clear first- or corresponding-author flagship papers were provided in the snapshot — this matters for interpreting independent leadership versus collaborative participation.
Metrics ambiguity: Multiple OpenAlex matches for the name "Dragan Maric" with widely varying h-indices (11, 67, 4, etc.) signal author disambiguation problems; relying on raw h-index without ORCID/institutional confirmation risks mis-attributing impact.
Reproducibility & methods transparency: from the provided titles alone we cannot fully assess experimental rigor (blinding, randomization, sample sizes) for each study; those require paper-level methods review.
Potential biases not yet evaluated: funding sources, conflicts of interest, pre-registration, and raw-data availability were not supplied — these can materially change perceived evidence strength.

What evidence would change this assessment?

Discovery of a distinct ORCID/public author profile showing a substantially higher independent first-/corresponding-author portfolio would raise the evaluation of independent leadership.
Detailed methods audits (showing poor controls, lack of blinding, small n, or irreproducible key experiments) in any of the highly-cited papers would lower confidence in technical rigor.
Conversely, detailed first-author method papers or public datasets and code associated with Maric would strengthen perceived rigor and reproducibility.

Recommended next steps for deeper evaluation

Resolve identity disambiguation: verify ORCID (provided: https://orcid.org/0000-0003-2912-7921) and institutional affiliation and cross-link to Scopus/PubMed author IDs.
Perform paper-by-paper methods audit: examine methods, n, blinding, code/data availability for key papers (Nature 2021; Mol Cell 2019; Sci Transl Med 2015).
Quantify independent leadership by counting first/corresponding-author papers and funding PI roles.
Request raw data access or check public repositories associated with the papers to evaluate reproducibility directly.

Primary source citations used in this review (representative high-impact papers)

Feedback:

Updated: March 17, 2026